BioXcel Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast

Rhea-AI Summary

BioXcel Therapeutics (BTAI) announced a conference call scheduled for May 12, 2020, at 8:30 AM ET, to discuss its Q1 2020 operating and financial results. The call will provide insights into the company’s performance in the clinical-stage biopharmaceutical sector, focusing on AI-driven therapy development in neuroscience and immuno-oncology. The company is known for its advanced programs, including BXCL501 for neuropsychiatric agitation and BXCL701 for rare prostate cancer and pancreatic cancer treatments.

Positive

• Focus on artificial intelligence for drug development in neuroscience and immuno-oncology.
• Advanced clinical programs including BXCL501 and BXCL701 show potential for significant market impact.

Negative

• None.

NEW HAVEN, Conn., May 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Tuesday, May 12, 2020 at 8:30 AM Eastern Time to discuss its first quarter 2020 operating and financial results.

Conference Call & Webcast Details
Date/Time: Tuesday, May 12, 2020, 8:30 AM Eastern Time
Domestic: 877-407-2985
International: 201-378-4915
The webcast will be accessible* under "Events" on the News & Media page of the Company's website at www.bioxceltherapeutics.com.

Replay
Domestic: 877-660-6853
International: 201-612-7415
Conference ID: 13703343
*Replay available through May 26, 2020

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.

Contact Information:
BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.com

Investor Relations:
John Graziano
jgraziano@troutgroup.com
1.646.378.2942

Media:
Julia Deutsch
jdeutsch@troutgroup.com
1.646.378.2967

FAQ

What time is BioXcel Therapeutics' conference call on May 12, 2020?

The conference call is scheduled for 8:30 AM Eastern Time on May 12, 2020.

What is the purpose of BioXcel Therapeutics' May 12, 2020 conference call?

The call will discuss the company's first quarter 2020 operating and financial results.

What are BioXcel Therapeutics' lead drug candidates?

BioXcel's lead candidates include BXCL501 for neuropsychiatric agitation and BXCL701 for certain cancers.